DFTX stock surged 50% after phase III data showed its single-dose investigational MDD therapy delivered rapid, durable symptom improvements and met all key trial goals. The readout is highly supportive for the program and materially improves the company’s clinical profile. While the move is stock-specific rather than sector-wide, the magnitude of the data and share reaction suggests a meaningful price impact.
DFTX stock surged 50% after phase III data showed its single-dose investigational MDD therapy delivered rapid, durable symptom improvements and met all key trial goals. The readout is highly supportive for the program and materially improves the company’s clinical profile. While the move is stock-specific rather than sector-wide, the magnitude of the data and share reaction suggests a meaningful price impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.82
